XLO Overview

Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.

Wall Street analysts forecast XLO stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for XLO is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

Xilio Therapeutics Inc revenue for the last quarter amounts to 13.69M USD, increased 693.85

Xilio Therapeutics Inc. EPS for the last quarter amounts to 0.95 USD, decreased -133.57

Xilio Therapeutics Inc (XLO) has 76 emplpoyees as of March 31 2026.

Today XLO has the market capitalization of 47.62M USD.